Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular and Fibrosis Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NPR1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NPR1 ECD-Fc Fusion Protein (Wild-type and mutant variants). High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View NPR1 Products |
| Gene Delivery | NPR1 Promise-ORF / Lentivirus Premade Particles. Full-length receptor with GC domain for stable cell lines. cGMP signaling competent. | View NPR1 Products |
| Benchmark Ab | Anti-NPR1. Recombinant positive control for assay standardization. | View NPR1 Products |
| Validator | NPR1 siRNA Set (3 unique sequences). For knockdown verification and specificity controls. | View NPR1 Products |
| Related Target A | NEP (Neprilysin). Key enzyme degrading natriuretic peptides; synergistic target for heart failure. | View NEP Products |
| Related Target B | NPR2 (GC-B). CNP receptor for selectivity screening (cGMP pathway homology). | View NPR2 Products |
| Related Target C | NPR3 (Clearance Receptor). Natriuretic peptide clearance receptor for off-target binding assessment. | View NPR3 Products |
| Related Target D | NPPA (ANP). Ligand protein for binding affinity assays and competition studies. | View NPPA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native glycosylation required for ANP/BNP binding affinity | HEK293 Expressed ECD-Fc with verified N-glycan profile (Mass Spec Confirmed) |
| Receptor internalization kinetics (agonist-induced trafficking) | Full-length NPR1 Lentivirus for stable cell line generation; preserve conformational dynamics |
| NPR1 vs NPR2 vs NPR3 selectivity | Ortholog panel: Human/Mouse/Cyno NPR1, NPR2, NPR3 proteins with >95% purity |
| cGMP functional validation | Validated siRNA included for loss-of-function confirmation in cell-based assays |
| Cell-Based Functional Assays (cGMP) | Lentivirus Premade Particles for rapid stable cell line construction preserving native conformation |
| Subfamily Counter Screening (NPR1 vs NPR2/3) | Homolog panel proteins (NPR2, NPR3) available, strictly verified by theoretical MW and sequence |
| Lack of Controls | Clinical Benchmark Antibodies included for assay standardization |
| False Positives | Validated siRNA included for specificity checks and background reduction |
Live NPR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Cardiovascular Research
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The NPR1 therapeutic landscape is undergoing a paradigm shift from acute vasodilator peptides (nesiritide analogs) toward chronic activation strategies targeting tissue-specific cGMP signaling. Major players are pivoting from traditional recombinant peptides to long-acting agonists, small molecule activators, and biased signaling modulators. Current R&D emphasizes long-acting NPR1 agonists with reduced hypotensive liability, kidney-selective formulations for cardio-renal protection, and combination therapies with neprilysin inhibitors. As first-generation biologics face PK limitations, the next wave targets biased signaling pathways and receptor internalization kinetics to achieve improved therapeutic windows. First-generation therapies for heart failure and hypertension are reaching maturity, while emerging indications include cardiac fibrosis, resistant hypertension, and metabolic disorders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Short-acting / First-gen Peptide Agonists | Novartis, J&J | Heart Failure, Hypertension | Receptor Binding Assay (Need high-purity ECD-Fc) |
| Long-acting Peptide Agonists | PhaseBio (former), Bayer | Heart Failure, Hypertension, Cardiac Fibrosis | Binding Affinity & Selectivity (Need high-purity ECD-Fc for SPR/BLI) |
| Small Molecule Modulators | Bayer, Merck, HighPoint Pharma | Resistant Hypertension, Acute Decompensated HF | cGMP Activation Assay (Need Lentivirus for Stable Cells) |
| Bi-functional Molecules | Various Biotech | Metabolic Disorders | Selectivity Assay (Need Homolog Panel Proteins) |
| NPR3 Antagonists (Indirect NPR1 activation) | Novartis, Ionis | Cardiac Fibrosis | Triple-receptor selectivity panel (NPR1/NPR2/NPR3 proteins required) |
| Gene Therapy (AAV-NPR1) | Academic Consortia | Chronic HF | Functional Overexpression Assay (Lentivirus for stable line validation) |